CRCbioscreen BV

Devoted to colorectal cancer early detection
Colorectal cancer (CRC) is one of the most common cancer types world wide, with about 1.8 million new cases and 0.9 million people dying from the disease annually.
Early detection and removal (“screening”) is the most effective approach for beating this disease, and the widely used Faecal Immunochemical Test (FIT) currently is the most cost effective method for this purpose
CRCbioscreen is developing a novel, multi-target Faecal Immunochemical Test (mt FIT), which has improved sensitivity for high risk precursor lesions, while maintaining the same low level of false postives as the current FIT has.